US Medicare And Opioids: Inspector General Sees Improvement
HHS is slowly changing its rhetoric on the use of prescription opioids – edging away from crisis to finding positive trends. A new OIG report on opioid use in Medicare Part D emphasizes sustained positive trends in naloxone rescue and medication assisted treatment alternatives to opioid use disorder.
You may also be interested in...
In announcing expedited assessments for new naloxone ANDAs, the agency also offers guidance to sponsors of discontinued products considering a return to marketing.
In State of the Department speech and HHS annual report, Secretary Azar trumpets historic number of approvals by FDA, and price cuts, roll backs or freezes by 'more than a dozen drug companies.'
US Senate Democrats are eager to bring in prescription opioid manufacturer executives for a hearing that would recreate the famous image of tobacco industry CEOs being sworn in by Congress. That moment probably won’t come this year – but may be inevitable before the opioid abuse crisis can be declared over.